Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

B. Riley Securities Initiates Coverage On Viridian Therapeutics with Buy Rating, Announces Price Target of $25

Author: Benzinga Newsdesk | June 23, 2022 06:09am
B. Riley Securities analyst Kalpit Patel initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Buy rating and announces Price Target of $25.

Posted In: VRDN